Old heart drug may help kidney transplant patients with low phosphate

NCT ID NCT06824454

Recruiting now Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether dipyridamole, a drug usually used for heart conditions, can raise low phosphate levels in kidney transplant recipients. Researchers will give the drug to 90 adult patients when their phosphate drops below normal. The goal is to see if it improves phosphate levels and cuts the need for phosphate supplements.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dipyridamole
What this could lead to: If it works, this could offer a new way to manage low phosphate after kidney transplant, reducing the need for supplements.
What could go wrong: This is a small, early-phase trial (90 people) testing an off-label drug. It may not show clear benefit, and results may not apply to all transplant patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPOPHOSPHATEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypophosphatemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPOPHOSPHATEMIA KIDNEY TRANSPLANTATION

Contacts and locations

Locations

Stanford University
RECRUITING

Stanford, California, 94304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.